[go: up one dir, main page]

DK1991237T3 - Kemoprotektive fremgangsmåder og sammensætninger - Google Patents

Kemoprotektive fremgangsmåder og sammensætninger Download PDF

Info

Publication number
DK1991237T3
DK1991237T3 DK06848549T DK06848549T DK1991237T3 DK 1991237 T3 DK1991237 T3 DK 1991237T3 DK 06848549 T DK06848549 T DK 06848549T DK 06848549 T DK06848549 T DK 06848549T DK 1991237 T3 DK1991237 T3 DK 1991237T3
Authority
DK
Denmark
Prior art keywords
bis
dithio
acceptable salt
administration
administered
Prior art date
Application number
DK06848549T
Other languages
English (en)
Inventor
Frederick H Hausheer
Original Assignee
Bionumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionumerik Pharmaceuticals Inc filed Critical Bionumerik Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1991237T3 publication Critical patent/DK1991237T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (7)

  1. ’ATENTKRAV I.
  2. 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ved mindskelse af bivirkninger som følge af overfølsomhed i forbindelse ned indgivelse af kemoterapeutika, hvor 2,2'-dithio-bis-ethansulfonatet eller det armaceutisk acceptable salt deraf skal indgives med en hastighed på 0,1 g/min til 2,0 ^/min.
  3. 1.
  4. 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 1, som skal indgives med en hastighed på 1 mg/ml/min til 50 mg/ml/min.
  5. 5.
  6. 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 1, som skal indgives i en totaldosis på 4 g/m2 til 35 g/m2.
  7. t. 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor det farmaceutisk acceptable salt er et dinatriumsalt, et mononatriumsalt, et natriumkaliumsalt, et Jikaliumsalt, et calciumsalt, et magnesiumsalt, et mangansalt, et ammoniumsalt eller at monokaliumsalt. 5. 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 4, hvor det farmaceutisk acceptable salt er dinatrium-2,2'-Jithio-bis-ethansulfonat. 5. 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge et hvilket som helst af kravene 1 til 5, som skal indgives fra én gang Jagligt til én gang hver femte uge. L 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor det kemoterapeutiske niddel er en taxananalog og/eller en platinanalog. 5. 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 7, hvor den taxananaloge er docetaxel eller paclitaxel. 9. 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 7, hvor den platinanaloge er cisplatin, carboplatin, oxaliplatin eller satraplatin. 10. 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge et hvilket som helst af kravene 1 til 9, som foreligger i en til oral indgivelse egnet form. 11. 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge et hvilket som helst af kravene 1 til 9, som foreligger i en til parenteral indgivelse egnet form. 12. 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 11, som foreligger i en til intravenøs indgivelse egnet form. 13. 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 1 til anvendelse ved nedsættelse af hyppigheden og sværheden af overfølsomhedsreaktioner og allergiske reaktioner, der fremkaldes af paclitaxel. 14. 2,2'-Dithio-bis-ethansulfonat eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 13, som skal indgives i et tidsrum på ca. 45 minutter og i en koncentration på ca. 100 mg/ml.
DK06848549T 2005-12-13 2006-12-13 Kemoprotektive fremgangsmåder og sammensætninger DK1991237T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75029205P 2005-12-13 2005-12-13
PCT/US2006/047619 WO2007070599A2 (en) 2005-12-13 2006-12-13 Chemoprotective methods and compositions

Publications (1)

Publication Number Publication Date
DK1991237T3 true DK1991237T3 (da) 2015-04-27

Family

ID=38163506

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06848549T DK1991237T3 (da) 2005-12-13 2006-12-13 Kemoprotektive fremgangsmåder og sammensætninger

Country Status (6)

Country Link
US (1) US8026227B2 (da)
EP (1) EP1991237B1 (da)
AU (1) AU2006326442B2 (da)
CA (1) CA2648945C (da)
DK (1) DK1991237T3 (da)
WO (1) WO2007070599A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111735A1 (en) * 2004-05-12 2009-04-30 Bionumerik Pharmaceuticals, Inc. Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US9801818B2 (en) 2007-12-31 2017-10-31 Samyang Biopharmaceuticals Corporation Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
WO2009084801A1 (en) * 2007-12-31 2009-07-09 Samyang Corporation Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same
KR101024742B1 (ko) * 2007-12-31 2011-03-24 주식회사 삼양사 탁산 함유 양친성 블록 공중합체 미셀 조성물 및 그 제조방법
US9320760B2 (en) * 2008-03-14 2016-04-26 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
ES2476602T3 (es) * 2008-03-14 2014-07-15 Bionumerik Pharmaceuticals, Inc. Composiciones y métodos quimioprotectores
WO2010033878A2 (en) 2008-09-19 2010-03-25 David Brown Solute concentration measurement device and related methods
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
EP2401587A2 (en) 2009-02-27 2012-01-04 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US8926561B2 (en) 2009-07-30 2015-01-06 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US11471431B2 (en) * 2010-09-16 2022-10-18 Lantern Pharma Inc. Increasing cancer patient survival time by administration of dithio-containing compounds
US9023805B2 (en) * 2010-09-16 2015-05-05 Bionumerik Pharmaceuticals, Inc. Increasing cancer patient survival time by administration of dithio-containing compounds
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6025488A (en) * 1994-11-14 2000-02-15 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5710188A (en) * 1997-03-19 1998-01-20 Morton International, Inc. PVC foam compositions
US6183461B1 (en) * 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
US7176192B2 (en) * 2001-10-26 2007-02-13 Bionumerik Pharmaceuticals, Inc. Method for treating patients for radiation exposure
US6596320B1 (en) * 2002-01-11 2003-07-22 Bionumerik Pharmaceuticals, Inc. Method for treating cancer having greater efficacy and reduced adverse effects
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity

Also Published As

Publication number Publication date
US20070135519A1 (en) 2007-06-14
EP1991237A4 (en) 2011-06-01
WO2007070599A3 (en) 2008-04-24
EP1991237A2 (en) 2008-11-19
EP1991237B1 (en) 2015-02-25
WO2007070599A2 (en) 2007-06-21
CA2648945A1 (en) 2007-06-21
AU2006326442A1 (en) 2007-06-21
AU2006326442B2 (en) 2012-03-01
US8026227B2 (en) 2011-09-27
CA2648945C (en) 2012-04-03

Similar Documents

Publication Publication Date Title
DK1991237T3 (da) Kemoprotektive fremgangsmåder og sammensætninger
US8143236B2 (en) Chemoprotective methods
AU2007227466B2 (en) Anti-cancer activity augmentation compounds and formulations and methods of use thereof
EP2063881B1 (en) A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
JP2007534730A (ja) 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物
ES2381968T3 (es) 2,2'-ditio-bis(etanosulfonato) para su uso en la inhibición de la termoestesia anómala inducida por paclitaxel
EP2252246B1 (en) Chemoprotective methods and compositions
DK2262493T3 (da) Behandlingsmetoder med længerevarende kontinuerlig infusion af belinostat
WO2019162756A2 (en) Liquid pharmaceutical compositions of anticancer drugs
CN114929213A (zh) 碱性化疗药瘤内注射剂组合物
DE102004045720A1 (de) Stabile Dosierungsform von Phenylalanin-Derivaten